Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer

"* Dose level 1 (DL1): 45 mg/m\^2 administered as a subcutaneous injection~* Dose level 1G (DL1G): 45 mg/m\^2 administered as a subcutaneous injection + growth factor support~* Dose level -1 (DL-1): 30 mg/m\^2 administered as a subcutaneous injection~* Dose level -1G (DL-1G): 30 mg/m\^2 administered as a subcutaneous injection + growth factor support"

160 mg taken orally

35 mg/m\^2 taken orally

45 mg/m\^2 administered as a subcutaneous injection

125 mg/m\^2 administered IV